CareFirst’s Class Action STELARA® Antitrust Case Against J&J Will Proceed: Court Grants-in-Part and Denies-in-Part Class Certification and Denies the Parties’ Motions for Summary Judgment

As we have previously reported, a group of health insurers and health insurance administrators (collectively, “CareFirst”) filed a class action complaint in 2023 against Johnson & Johnson and Janssen Biotech, Inc. (collectively, J&J), alleging multiple violations of federal and state antitrust laws arising from J&J’s STELARA® (utsekinumab) product, as well as violations of state consumer protection laws and unjust enrichment claims….
By: Goodwin